Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

被引：0
|
作者：
Fontana, A. [1 ]
Galli, L. [2 ]
Derosa, L. [2 ]
Minuti, G. [2 ]
D'Arcangelo, M. [2 ]
Bursi, S. [2 ]
Landi, L. [2 ]
Bocci, G. [3 ]
Santini, D. [4 ]
Falcone, A. [3 ]
机构：
[1] Azienda Osped Univ Pisana, Pisa, Italy
[2] ASL6 Livorno, Med Oncol, Livorno, Italy
[3] Univ Pisa, Pisa, Italy
[4] Univ Campus Biomed, Rome, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71414-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：417 / 417
页数：1
相关论文
共 50 条
  • [31] Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer
    Chi, K. N.
    Hotte, S. J.
    Yu, E.
    Tu, D.
    Eigl, B.
    Tannock, I.
    Saad, F.
    North, S.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).
    Emmenegger, U.
    Berry, S. R.
    Booth, C. M.
    Sridhar, S. S.
    Winquist, E.
    Bandali, N.
    Chow, A.
    Kerbel, R.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC)
    Emmenegger, U.
    Berry, S. R.
    Booth, C.
    Sridhar, S. S.
    Winquist, E.
    Bandali, N.
    Chow, A.
    Kerbel, R. S.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [34] A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC)
    Emmenegger, U.
    Sridhar, S. S.
    Booth, C. M.
    Kerbel, R.
    Berry, S. R.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial
    van Dodewaard-de Jong, Joyce M.
    de Klerk, John M. H.
    Bloemendal, Haiko J.
    Oprea-Lager, Daniela E.
    Hoekstra, Otto S.
    van den Berg, H. Pieter
    Los, Maartje
    Beeker, Aart
    Jonker, Marianne A.
    O'Sullivan, Joe M.
    Verheul, Henk M. W.
    van den Eertwegh, Alfons J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (08) : 1319 - 1327
  • [36] A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial
    Joyce M. van Dodewaard-de Jong
    John M. H. de Klerk
    Haiko J. Bloemendal
    Daniela E. Oprea-Lager
    Otto S. Hoekstra
    H. Pieter van den Berg
    Maartje Los
    Aart Beeker
    Marianne A. Jonker
    Joe M. O’Sullivan
    Henk M. W. Verheul
    Alfons J. M. van den Eertwegh
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1319 - 1327
  • [37] A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)
    Leibrandt, Ryan
    Ullah, Ayman Teeham
    Verma, Rashmi
    Gao, Allen
    Lara, Primo N., Jr.
    Pan, Chong-xian
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Docetaxel in combination with Temsirolimus in patients with advanced castration resistant prostate cancer (CRPC): A phase II trial of the Spanish Oncology Genitourinary Group
    Duran, I.
    Rodriguez-Moreno, J. F.
    Lainez, N.
    Climent Duran, M. A.
    Leon, L.
    Garcia-Carbonero, I.
    Garcia-Donas, J.
    Viqueira, A.
    Bellmunt, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S704 - S704
  • [39] A phase II study of abiraterone acetate plus prednisone in patients with castration resistant prostate cancer (CRPC) and no prior therapy with ketoconazole
    Ryan, C.
    Harzstark, A.
    Fong, L.
    Lin, A.
    Kilian, C.
    Molina, A.
    Small, E. J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 81 - 81
  • [40] METRONOMIC ORAL VINORELBINE (V) AND DEXAMETHASONE (D) IN PATIENTS WITH ADVANCED CASTRATION RESISTANT PROSTATE CANCER (CRPC): A PHASE II CLINICAL STUDY WITH PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) EVALUATIONS
    Galli, L.
    Fontana, A.
    Derosa, L.
    Minuti, G.
    D'Arcangelo, M.
    Fontana, E.
    Safina, V
    Landi, L.
    Bursi, S.
    Galli, C.
    Bona, E.
    Bocci, G.
    Antonuzzo, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
12345